Wellcome Leap

What Wellcome Leap does

Wellcome Leap Inc. is a US 501(c)(3) nonprofit research funding organization founded in 2020 by the Wellcome Trust with $300 million in initial grant capital, incorporated in San Diego. It operates as a "global ARPA for health," applying the DARPA program-management model — bold targets, tight timelines, multi-disciplinary teams, results-based program termination — to complex human-health problems. Core operations consist of designing, funding, and executing a portfolio of 16 thematic programs (e.g., Q4Bio quantum computing for biology, HOPE bioengineered organs, Dynamic Resilience healthy aging, VISIBLE and The Missed Vital Sign in women's health, Resistance Networks in antimicrobial resistance) typically funded at $45-60M each and structured for 3-5 year delivery against audacious goals such as reducing stillbirths by half or achieving quantum advantage for drug discovery.

Execution runs through the proprietary Health Breakthrough Network (HBNet), a standardized research network of 170+ institutions across six continents representing more than 1,500,000 researchers. HBNet is enabled by Master Academic Research Funding Agreements (MARFA/CORFA) that allow funded projects to begin in days rather than the 6-12 months typical of academic grant administration. Programs are steered by dedicated Program Directors, several drawn from institutions such as Oxford, Cambridge, and Idorsia Pharmaceuticals, and supported by an in-house leadership team with deep operational pedigree (former DARPA Director, former Illumina CEO, former Goldman Sachs Vice Chairman).

The revenue model is philanthropic rather than commercial: Wellcome Leap receives grant funding from its founding parent the Wellcome Trust and a growing set of co-funding strategic partners including Pivotal Ventures ($100M for women's health), Temasek Trust ($60M for Dynamic Resilience), Bayer ($50M for Resistance Networks), and IBM Quantum (in-kind hardware for Q4Bio). It does not sell products or services, does not license technology for revenue, and does not publicly disclose annual receipts. Target "customers" are the research institutions, biotech firms, and clinical partners that compete for program funding and use HBNet as a collaboration backbone.

Name

Wellcome Leap

Legal name

Wellcome Leap Inc.

Website

https://wellcomeleap.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Wellcome Leap is a US 501(c)(3) nonprofit that operates as a "global ARPA for health," funding 16 bold $45-60M research programs across 30 countries and a 170-institution network to accelerate health breakthroughs in 5-10 years.

Ownership category

akta.pro rank

Product category

Health Research Funding

NAICS

Voluntary Health Organizations (813212), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Social Services (8300), Services-Health Services (8000)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Health research funding
• Nonprofit health innovation
• Biomedical research programs
• Philanthropic research grants
• Global health initiatives

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Philanthropic Grant Funding: Wellcome Leap is a non-profit organization funded by the Wellcome Trust and other strategic partners. The organization deploys grant funding to accelerate health breakthroughs through unconventional programs executed at scale. Initial funding of $300 million was provided by the Wellcome Trust in 2020.
2. Co-Funded Programs: Strategic partnerships where co-funding partners co-invest in specific programs. Examples include: $55M VISIBLE program with Pivotal, $60M Dynamic Resilience with Temasek Trust, $50M Resistance Networks with Bayer, and $100M women's health partnership with Pivotal Ventures.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Wellcome Leap is a US 501(c)(3) nonprofit that builds and executes bold, unconventional health research programs funded at scale ($45-60M each), applying a DARPA-inspired innovation model to accelerate breakthroughs in human health over 5-10 year timelines. The organization runs 16 programs across 30 countries — including Q4Bio (quantum computing for biology), HOPE (bioengineered organs), Dynamic Resilience (healthy aging), and women's health programs (VISIBLE, The Missed Vital Sign, In Utero, CARE) — coordinated through the Health Breakthrough Network of 170+ research institutions representing 1.5 million researchers.

Product overview

Wellcome Leap is a billion-dollar breakthrough engine for human health operating as a global ARPA-style funding model. The organization builds and executes bold, unconventional programs funded at scale, targeting complex human health challenges with the goal of achieving breakthrough scientific and technological solutions in years, not decades. The portfolio consists of 16 distinct research programs across diverse health areas including quantum computing for biology (Q4Bio), healthy aging and resilience (Dynamic Resilience), organ engineering (HOPE), women's health (VISIBLE, The Missed Vital Sign, In Utero, CARE), addiction treatment, infectious disease preparedness (R3 Global), and various other therapeutic areas. These programs are supported by the Health Breakthrough Network (HBNet), the world's largest research network spanning 170+ institutions across six continents. Programs range from $45M to $60M in funding and operate over 3-5 year timelines with ambitious goals such as eliminating dialysis, reducing stillbirths by half, or achieving quantum advantage for drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• Leap Health Breakthrough Network (HBNet): The world's largest research network dedicated to accelerating breakthroughs in human health, with over 170 organizations on 6 continents representing more than 1,500,000 researchers.

Products and services

• Q4Bio (Quantum for Bio) A $50 million supported challenge program that brought together quantum software, hardware, and biology experts to develop algorithms demonstrating quantum advantage for health applications. The program culminated in Algorithmiq winning $2M for an end-to-end quantum-classical workflow simulating photodynamic cancer therapy drugs.
• Dynamic Resilience A $60 million program jointly funded with Temasek Trust focused on identifying and validating causal measures and models of health resilience with predictive value sufficient to make clinical decisions and support development of preventative interventions for healthy aging.
• HOPE (Human Organs, Physiology, and Engineering)

Quantifiable outcome

• 90% of treatments succeed in animal studies but fail in humans — Wellcome Leap programs aim to transform preclinical prediction
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

13 partnerships are on record, tiered core and flagship.

• The Menopause SocietycoreStrategic or Co-development Partner · 4 June 2026Partner in Melinda French Gates' $215M women's health commitment alongside Wellcome Leap, focusing on access to care during reproductive years, midlife, menopause, and mental health.
• World Economic ForumcoreStrategic or Co-development Partner · 21 May 2026Collaborated on Women's Health Innovation Radar report identifying systemic gaps in R&D funding — only 20% of research funding is women-focused, women-focused research accounts for 16% of publications and fewer than 3% of clinical trials.
• Kearney Health InstitutecoreStrategic or Co-development Partner · 21 May 2026Partnered with World Economic Forum and Wellcome Leap on Women's Health Innovation Radar report analyzing R&D investment patterns from 2016-2025 for 10 high-impact conditions.
• Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 21 May 2026Collaborated on Women's Health Innovation Radar report identifying allocation gap, evidence gap, and translation gap in women's health R&D funding.
• IBM QuantumcoreTechnology or Integration · 16 April 2026IBM provided quantum computing hardware support for the Q4Bio challenge program. Five of six Phase III finalist teams used IBM quantum hardware for research spanning drug discovery, genomics, and biomarker discovery, utilizing 100+ qubit processors with circuit depths of 1,000 to 10,000 gates.
• Cleveland CliniccoreStrategic or Co-development Partner · 16 April 2026Cleveland Clinic provided biological expertise for the Q4Bio challenge, collaborating with Algorithmiq and IBM to demonstrate scalable quantum algorithms for photodynamic therapy simulation in cancer treatment.
• AlgorithmiqcoreStrategic or Co-development Partner · 16 April 2026Helsinki-based quantum computing startup won the $2 million Phase III prize in Q4Bio for demonstrating an end-to-end quantum-classical workflow for drug discovery on real quantum hardware, simulating activation pathways of a photosensitiser cancer drug.
• University of OxfordcoreStrategic or Co-development Partner · 15 April 2026Researchers encoded the complete genome of hepatitis D virus onto an IBM 156-qubit quantum processor — first-ever complete genome loaded onto a quantum computer — as part of Q4Bio Quantum Pangenome project.
• Wellcome Sanger InstitutecoreStrategic or Co-development Partner · 15 April 2026Contributed to Quantum Pangenome project under Q4Bio, encoding complete hepatitis D virus genome onto quantum processor to demonstrate quantum computing potential for genomic analysis.
• InfleqtioncoreStrategic or Co-development Partner · 5 February 2026Selected to advance to Phase 3 of Q4Bio challenge, collaborating with University of Chicago and MIT on applying hybrid quantum-classical workflows to forecast treatment response in head-and-neck cancer using clinical data.
• Medicines360coreStrategic or Co-development Partner · 12 January 2026Partnership to accelerate development and access to new lifesaving pregnancy and stillbirth risk-reduction tools for women worldwide, announced January 2026.
• Pivotal VenturesflagshipStrategic or Co-development Partner · 10 September 2025Historic $100 million partnership between Wellcome Leap and Pivotal Ventures (Melinda French Gates organization) to advance women's health research through innovative programs. The partnership focuses on cardiovascular, autoimmune, and mental health issues affecting women, with a grant process inspired by DARPA aiming to generate significant health improvements within three to five years. Total commitment to women's health now exceeds $250M.
• Spark BiomedicalcoreStrategic or Co-development Partner · 19 August 2025Awarded funding from Wellcome Leap for The Missed Vital Sign women's health initiative, supporting clinical trials of transcutaneous auricular neurostimulation (tAN) platform for heavy menstrual bleeding, including women with von Willebrand Disease.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• ARPA-H: U.S. federal Advanced Research Projects Agency for Health, launched 2022 to apply ARPA-style program management to biomedical breakthroughs. Most direct comparable as both organizations explicitly apply the DARPA model to human health with similar program structures and timelines.
• Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership that accelerates development of vaccines against epidemic threats. Comparable as a multi-funder, mission-driven organization funding coordinated global research programs toward specific health breakthroughs with defined timelines.
• Foundation for the National Institutes of Health (FNIH): Nonprofit that manages public-private partnerships supporting NIH mission areas, often with multi-million-dollar multi-stakeholder programs. Comparable as a non-governmental entity orchestrating large-scale biomedical research programs across institutions.

Broad incumbents

• Howard Hughes Medical Institute (HHMI): Major biomedical research organization funding investigator-initiated science across U.S. universities. Comparable in scale and ambition for breakthrough science, but uses a sustained-investigator model rather than DARPA-style time-bound programs.
• Chan Zuckerberg Initiative (CZI): Philanthropic initiative of Mark Zuckerberg and Priscilla Chan with substantial biomedical research funding including the Chan Zuckerberg Biohub network. Comparable as a large-scale private science funder focused on ambitious long-horizon health challenges.
• Gates Foundation: Bill & Melinda Gates Foundation is one of the largest global health funders, with explicit collaboration with Wellcome Leap on the Women's Health Innovation Radar report. Comparable as a massive-scale philanthropic health R&D funder with global program reach.
• Wellcome Trust: Wellcome Leap's parent foundation, one of the world's largest charitable foundations focused on health research. Directly comparable as a global health research funder, and Wellcome Leap was created to apply a different (DARPA-style) operating model on top of the parent organization's traditional funding approach.
• Novo Nordisk Foundation: Major Danish philanthropic foundation funding biomedical research, biotechnology, and innovation at significant scale. Comparable as a large European foundation making multi-year, multi-hundred-million-dollar bets on health breakthroughs.

Emerging players

• Schmidt Futures: Philanthropic initiative of Eric and Wendy Schmidt funding ambitious science and technology programs. Comparable as a newer-generation philanthropic funder focused on breakthrough research with unconventional program structures.

Regional players

• BARDA (Biomedical Advanced Research and Development Authority): U.S. government agency within HHS that funds development of medical countermeasures. Comparable in funding advanced translational R&D at scale, but primarily U.S.-focused and government-operated rather than philanthropic.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/wellcomeleap
• LinkedInlinkedin.com/company/wellcome-leap
• Instagraminstagram.com/wellcomeleap

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellcome Leap